Evaluation of the effect of miltefosine on Trichomonas vaginalis

Parasitology Research

Volumn 113, Issue 3, 2014, Pages 1041-1047

  Rocha, Débora Afonso Silva ^a,b   De Andrade Rosa, Ivone ^a,b   De Souza, Wanderley ^b,c   Benchimol, Marlene ^a  

^a UNIVERSIDADE SANTA ÚRSULA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; IC 50; IN VITRO STUDY; NONHUMAN; PARASITE VIABILITY; PRIORITY JOURNAL; TRICHOMONAS VAGINALIS;

ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITORY CONCENTRATION 50; PHOSPHORYLCHOLINE; TRICHOMONAS VAGINALIS;

EID: 84895548126     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-013-3738-z     Document Type: Article

References (55)

1. Bertão HG, da Silva RA, Padilha RJ, de Azevedo Albuquerque MC, Rádis-Baptista G (2012) Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms. Parasitol Res 110:2465-2473
2. Blaha C, Duchêne M, Aspöck H, Walochnik J (2006) In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole- resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother 57:273-278
3. Cabrera-Serra MG, Lorenzo-Morales J, Romero M, Valladares B, Piñero JE (2007) In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol Res 100:1155-1157
4. Clive S, Gardiner J, Leonard RC (1999) Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemother Pharmacol 44:S29-S30
5. Cotch MF, Pastorek JG, Nugent RP, Hillier SL, Gibbs RS, Martin DH, Eschenbach DA, Edelman R, Carey JC, Regan JA, Krohn MA, Klebanoff MA, Rao AV, Rhoads GG (1997) Trichomonas vaginalis associated with low birth weight and preterm delivery. The vaginal infections and prematurity study group. Sex Transm Dis 24:353-360
6. Croft SL, Neal RA, Pendergast W, Chan JH (1987) The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 36:2633-2636
7. Croft SL, Snowdon D, Yardley V (1996) The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38:1041-1047
8. Diamond LS (1957) The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 43:488-490
9. Edwards DI (1993) Nitroimidazole drugs - action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31:9-20
10. Eissa MM, Amer EI (2012) Giardia lamblia: a new target for miltefosine. Int J Parasitol 42:443-452
11. Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM (2011a) Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol 41:235-242
12. Eissa MM, El Bardicy S, Tadros M (2011b) Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy. Parasitol Vectors 4:73
13. Escobar P, Matu S, Marques C, Croft SL (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81:151-157
14. Hilgard P, Klenner T, Stekar J, Unger C (1993) Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32:90-95
15. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795-1800
16. Johnston VJ, Mabey DC (2008) Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 21:56-64
17. Khademvatan S, Gharavi MJ, Rahim F, Saki J (2011) Miltefosine-induced apoptotic cell death on Leishmania major and L. tropica strains. Korean J Parasitol 49:17-23
18. Kuhlencord A, Maniera T, Eibl H, Unger C (1992) Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36:1630-1634
19. Kulda J, VojtÄchovská M, Tachezy J, Demes P, Kunzová E (1982) Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis - a case report. Br J Ven Dis 58:394-399
20. Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB (1991) Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 88:279-280
21. Lira R, Contreras LM, Rita RM, Urbina JA (2001) Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47:537-546
22. Lossick JG, Muller M, Gorrell TE (1986) In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 153:948-955
23. Lossick JG (1990) Treatment of sexually transmitted vaginosis/vaginitis. Rev Infect Dis Suppl 6:S665-681
24. Madeiro da Costa RF, Benchimol M (2004) The effect of drugs on cell structure of Tritrichomonas foetus. Parasitol Res 92:159-170
25. Mariante RM, Guimarães CA, Linden R, Benchimol M (2003) Hydrogen peroxide induces caspase activation and programmed cell death in the amitochondrial Tritrichomonas foetus. Histoch Cell Biol 120:129-141
26. Mariante RM, Vancini RG, Benchimol M (2006) Cell death in trichomonads: new insights. Histoch Cell Biol 125:545-556
27. Martin MB, Grimley JS, Lewis JC, Heath HT, Bailey BN, Kendrick H, Yardley V, Caldera A, Lira R, Urbina JA, Moreno SN, Docampo R, Croft SL, Oldfield E (2001) Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 44:909-916
28. Meingassner JG, Thurner J (1979) Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother 15:254-257
29. Meri T, Jokiranta TS, Suhonen L, Meri S (2000) Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol 38:763-767
30. Muller M, Meingassner JG, Miller WA, Ledger WJ (1980) Three metronidazole-resistant strains of Trichomonas vaginalis from the United States. Am J Obstet Gynecol 138:808-812
31. Noel JC, Fayt I, Romero Munoz MR, Simon P, Engohan-Aloghe C (2010) High prevalence of high-risk human papillomavirus infection among women with Trichomonas vaginalis infection on monolayer cytology. Arch Gynecol Obstet 282:503-505
32. Polat ZA, Obwaller A, Vural A, Walochnik J (2012) Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. Parasitol Res 110:515-520
33. Robinson SC (1962) Trichomonal vaginitis resistant to metranidazole. Can Med As J 86:665-666
34. Rosa IA, Rocha DA, de Souza W, Urbina JA, Benchimol M (2011) Ultrastructural alterations induced by Δ(24(25))-sterol methyltransferase inhibitors on Trichomonas vaginalis. FEMS Microbiol Lett 315:72-78
35. Santa-Rita RM, Santos Barbosa H, Meirelles MN, de Castro SL (2000) Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 75:219-228
36. Santa-Rita RM, Barbosa HS, de Castro SL (2006) Ultrastructural analysis of edelfosine-treated trypomastigotes and amastigotes of Trypanosoma cruzi. Parasitol Res 100:187-190
37. Saraiva VB, Gibaldi D, Previato JO, Mendonça-Previato L, Bozza MT, Freire-De-Lima CG, Heise N (2002) Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother 46:3472-3477
38. Saraiva VB, Wengert M, Gomes-Quintana E, Heise N, Caruso-Neves C (2009) Na(+)-ATPase and protein kinase C are targets to 1-O-hexadecylphosphocoline (miltefosine) in Trypanosoma cruzi. Arch Biochem Biophys 481:65-71
39. Secor WE (2012) Trichomonas vaginalis: treatment questions and challenges. Expert Rev Anti Infect Ther 10:107-109
40. Seifert K, Duchêne M, Wernsdorfer WH, Kollaritsch H, Scheiner O, Wiedermann G, Hottkowitz T, Eibl H (2001) Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 45:1505-1510
41. Serrano-Martín X, Payares G, De Lucca M, Martinez JC, Mendoza-León A, Benaim G (2009) Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53:5108-5113
42. Shakya N, Sane SA, Gupta S (2011) Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator - picroliv. Parasitol Res 108:793-800
43. Shakya N, Sane SA, Haq W, Gupta S (2012) Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis. Parasitol Res 111:563-570
44. Smilack JD, Wilson WR, Cockerill FR III (1991) Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin Proceed 66:1270-1280
45. Soper D (2004) Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol 190:281-290
46. Sorvillo F, Kerndt P (1998) Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 351:213-214
47. Sorvillo F, Smith L, Kerndt P, Ash L (2001) Trichomonas vaginalis, HIV and African-Americans. Emerg Infect Dis 7:927-932
48. Soto J, Soto P (2006) Current situation and future of anti-leishmanial therapy in Colombia. Biomedica 1:194-206
49. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H (2004) Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38:1266-1272
50. Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos CA, Zenilman JM, De Marzo AM, Willett WC, Platz EA (2006) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemio Biom Prev 15:939-945
51. Van Der Pol B, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen PL, van de Wijgert J, Mmiro F, Mugerwa R, Chipato T, Morrison CS (2008) Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 197:548-554
52. Walochnik J, Duchêne M, Seifert K, Obwaller A, Hottkowitz T, Wiedermann G, Eibl H, Aspock H (2002) Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother 46:695-701
53. Widmer F, Wright LC, Obando D, Handke R, Ganendren R, Ellis DH, Sorrell TC (2006) Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 50:414-421
54. World Health Organization (WHO) (2001) Global prevalence and incidence of selected curable sexually transmitted infections. In Global Program on AIDS, Geneva, Switzerland: World Health Organization 2-27
55. Zhang ZF, Begg CB (1994) Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol 23:682-690